PI
SMMT icon

PEAK6 Investments’s Summit Therapeutics SMMT Stock Holding History

PEAK6 Investments’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$87.6K Buy
+4,000
New +$55.9K ﹤0.01% 3015

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

PEAK6 Investments's SMMT Position: Q3 2024 in Review

PEAK6 Investments opened a new position in Summit Therapeutics (SMMT) in Q3 2024: 4,000 shares worth $87.6K. The stake represents ﹤0.01% of the portfolio and ranks #3015 among its holdings.

166 funds tracked by Wall St. Rank hold SMMT as of Q3 2024.

  • PEAK6 Investments held 4,000 shares of Summit Therapeutics worth $87.6K as of Q3 2024.
  • Summit Therapeutics was a new PEAK6 Investments position in Q3 2024.
  • Summit Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #3015 holding.
  • 166 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.